CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML

Great news for older patients (over 60) with AML – there is a new combination drug that improves the chances of cure and survival. The long term survival is almost twice as good as the survial after the standard chemotherapy. The full publication can be found in JCO: https://www.ncbi.nlm.nih.gov/pubmed/30024784

FDA Approval Summary: https://www.ncbi.nlm.nih.gov/pubmed/30541745

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s